This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Pfizer Corporation, Merck Sharp + Dohme Corp.. Active years: 1994-2020.
Location History:
- Groton, CT (US) (1994)
- La Jolla, CA (US) (2020)
Company Filing History:
2 out of 4,486 
1 out of 2,405 
Years Active: 1994-2020
Title: Keith David Wilner: Innovator in Cancer Treatment and Analgesics
Introduction
Keith David Wilner is a notable inventor based in La Jolla, California. He has made significant contributions to the field of medicine, particularly in cancer treatment and pain management. With a total of 2 patents, his work focuses on innovative therapies that address critical health issues.
Latest Patents
Wilner's latest patents include a combination of a PD-1 antagonist and an ALK inhibitor for treating cancer. This patent describes combination therapies that utilize an antagonist of the Programmed Death 1 receptor (PD-1) alongside an Anaplastic Lymphoma Kinase (ALK) inhibitor. The therapies are designed for the treatment of cancers that test positive for ALK, PD-L1, or both. Another significant patent involves the use of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic. This method aims to produce analgesia and treat anti-inflammatory diseases while minimizing the risk of proteinuria in human subjects.
Career Highlights
Throughout his career, Wilner has worked with prominent companies in the pharmaceutical industry, including Pfizer Corporation and Merck Sharp & Dohme Corp. His experience in these organizations has contributed to his expertise in developing innovative medical solutions.
Collaborations
Wilner has collaborated with talented professionals in his field, including Leena Das-Young and Kelvin Cooper. These partnerships have likely enhanced his research and development efforts, leading to impactful inventions.
Conclusion
Keith David Wilner's contributions to medical innovation, particularly in cancer treatment and analgesics, highlight his role as a significant inventor. His patents reflect a commitment to improving patient outcomes through advanced therapies.